Chronic Kidney Disease Drugs Market Size & Share Report 2034

Chronic Kidney Disease Drugs Industry Perspective:

What will be the global chronic kidney disease drugs market size during the forecast period?

The global chronic kidney disease drugs market size was worth around USD 14.82 billion in 2024 and is predicted to grow to around USD 23.80 billion by 2034, with a compound annual growth rate (CAGR) of roughly 4.23% between 2025 and 2034.

Request Free Sample

Key Insights:

• As per the analysis shared by our research analyst, the global chronic kidney disease drugs market is estimated to grow annually at a CAGR of around 4.23% over the forecast period (2025-2034)
• In terms of revenue, the global chronic kidney disease drugs market size was valued at around USD 14.82 billion in 2024 and is projected to reach USD 23.80 billion by 2034.
• The chronic kidney disease drugs market is projected to grow at a significant rate due to the growing number of diabetic patients across the globe.
• Based on the drug class, the angiotensin-converting enzyme (ACE) inhibitors segment is growing at a high rate and will continue to dominate the global market, as per industry projections
• Based on the indication, the diabetic neuropathy segment is anticipated to command the largest market share
• Based on region, North America is projected to dominate the global market during the forecast period

Chronic Kidney Disease Drugs Market: Overview

Chronic kidney disease (CKD) drugs are medications specifically designed to treat kidney-related conditions. It includes drugs that can either slow disease progression or help patients deal with the symptoms. The type of drugs prescribed by a medical professional to patients suffering from chronic kidney disease depends on the reasons for the medical conditions. The most common medications prescribed for diabetes-induced chronic kidney disease are SGLT2 inhibitors and insulin. Similarly, the prescribed drugs may vary depending on the actual condition causing kidney disease, severity, and overall health of the patients. The demand for chronic kidney disease drugs is projected to grow, driven by the rising number of diabetic patients worldwide.

Additionally, growing advancements in medical research & development (R&D) may open new avenues for extended growth in the industry. A major drawback for industry players may result in the form of higher R&D costs and limited healthcare infrastructure in certain parts of the world.

Chronic Kidney Disease Drugs Market: Dynamics

Growth Drivers

What will be the influence of rising diabetic patients on the growth of the chronic kidney disease drugs market?

The global chronic kidney disease drugs market is expected to be driven by the growing number of diabetic patients across the globe. According to the World Health Organization (WHO), more than 830 million cases of diabetes were reported in 2022. However, research suggests that the number of diabetic patients is higher due to the large volume of undocumented cases. Factors contributing to diabetes across all age groups include genetic and environmental factors.

For instance, poor eating habits, a sedentary lifestyle, and frequent smoking or alcohol consumption are the most common reasons that lead to high blood sugar levels. Genetic conditions such as cystic fibrosis-related diabetes, mitochondrial diabetes, and neonatal diabetes mellitus continue to impact the lives of common people around the globe. High diabetes is known to have a severe impact on kidney function over time. As per industry analysis, around 35% to 40% diabetes patients tend to suffer from CKD at some point in their lives. Such statistics are expected to fuel demand for effective treatment options for chronic kidney diseases caused by diabetes.

Rising patient awareness and focus on early CKD detection to offer improved revenue in the industry

Patient awareness about chronic kidney diseases has improved significantly over the years. Increasing health campaigns undertaken by government and private companies, along with easy access to information through digital media channels, are the most prominent factors influencing improved patient awareness. In addition, a growing number of medical researchers are working on the early detection of CKD to provide more effective medical care to patients. These factors will work in favor of the global chronic kidney disease drugs market players in the coming years.

Restraints

How will stringent regulatory hurdles limit the chronic kidney disease market growth rate?

The global chronic kidney disease drugs industry is projected to be constrained by a strict regulatory environment that limits market growth. Approval and launch of new drugs are subject to authorizations from relevant regulatory bodies such as the US Food & Drug Administration (FDA) and the European Medicines Agency authorities. However, obtaining official certifications and permission for commercial sale is a resource-intensive task requiring significant investment. This can create significant growth barriers for the industry players in the future.

Opportunities

Novel drug development to offer significant growth opportunities to the industry players

The global chronic kidney disease drugs market is expected to generate growth opportunities due to the rising development of novel drugs. Some of the most promising areas of advancements in CKD drug development include integration of combination therapy approaches for multi‑pathway CKD management and development and approval of novel oral Hypoxia-Inducible Factor (HIF) prolyl hydroxylase inhibitors for anemia in CKD.

In September 2023, the US FDA approved the use of Empaglifozin for treating kidney disease in adults. The drug is a 10 mg pill that must be consumed every day. During clinical trials, Empaglifozin was highly effective in reducing estimated glomerular filtration rate (eGFR) and in reducing the incidence of kidney failure and hospitalization. In November 2025, results from the FINE-ONE test, a multinational clinical trial, confirmed that the drug finerenone significantly reduced the urine albumin-to-creatinine ratio (UACR), which is associated with a higher risk of CKD progression to kidney failure. The medicine works by limiting overactivity in the hormone aldosterone, which is known to cause kidney damage.

Challenges

Which challenges will the high cost of R&D create for chronic kidney disease drug market players?

The global chronic kidney disease drugs industry is projected to be challenged by the high cost of R&D associated with the market. Developing new drugs and treatments for CKD is highly cost-intensive due to the expenses associated with long research procedures, followed by complex clinical trials and regulatory approvals. Developing a novel drug can cost anywhere between USD 2 billion and USD 2.5 billion. Such high investment numbers limit the number of players operating in the market.

Request Free Sample

Chronic Kidney Disease Drugs Market: Report Scope

Chronic Kidney Disease Drugs Market: Segmentation

The global chronic kidney disease drugs market is segmented based on drug class, route of administration, indication, distribution channel, and region.

Why is the angiotensin-converting enzyme (ACE) inhibitor segment leading the chronic kidney disease drugs market?

Based on drug class, the global market is divided into angiotensin-converting enzyme (ACE) inhibitors, beta-blockers, angiotensin receptor blockers (ARBs), loop diuretics, phosphate binders, erythropoiesis-stimulating agents, calcium channel blockers, and others. In 2024, the highest growth was listed in the angiotensin-converting enzyme (ACE) inhibitors segment, dominating nearly 25.01% of total revenue. ACE inhibitors are the primary drugs prescribed to patients suffering from CKD. Their role as the first line of treatment in treating kidney-related conditions will help the segment thrive during the projection period.

Based on the route of administration, the global chronic kidney disease drugs industry is divided into parenteral and oral.

What position does the angiotensin-converting enzyme (ACE) inhibitors segment hold in the chronic kidney disease drugs industry?

Based on the indication, the global market divisions are polycystic kidney disease, hypertensive neuropathy, glomerulonephritis, diabetic neuropathy, and others. In 2024, the highest market growth was listed in the diabetic neuropathy segment, dominating nearly 63% of total revenue. The global surge in the number of diabetic patients and the adverse effects of hyperglycemia on renal function will increase future segmental demand.

Based on distribution channels, the global market is fragmented into online pharmacies, retail pharmacies, and hospital pharmacies.

Chronic Kidney Disease Drugs Market: Regional Analysis

Why will North America continue to dominate the chronic kidney disease drugs market?

The global chronic kidney disease drugs market is expected to be dominated by North America during the projection period. According to industry research, the region will deliver a CAGR of more than 7.01% in the coming years, with the US leading the regional revenue. The presence of a robust and thriving medical infrastructure across North America is a primary growth driver for CKD drugs. In addition, growing regulatory approvals and increasing investments in novel drug development will aid future growth in the region. In 2020, U.S. medical and health research and development investments totaled over USD 245 billion, according to official statistics, and are projected to increase in the coming years.

At what CAGR is Asia Pacific expected to grow in the chronic kidney disease drugs industry?

The Asia-Pacific region is projected to be the fastest-growing market, with a CAGR of 8.21% over the forecast period. Rising healthcare research in countries such as China and India will facilitate improved revenue in the region. Additionally, the growing number of patients suffering from CKD, especially diabetes-induced chronic kidney disease, will promote increased demand for medical drugs. The regional governments are expected to increase healthcare funding in the coming years as regional demand for high-quality healthcare continues to rise.

Chronic Kidney Disease Drugs Market: Competitive Analysis

The global chronic kidney disease drugs market is led by players like:

• Boehringer Ingelheim
• AstraZeneca
• Novartis
• Merck & Co.
• Sanofi
• Takeda Pharmaceutical
• Roche
• Johnson & Johnson
• AbbVie
• GlaxoSmithKline
• Pfizer
• Eli Lilly
• Bristol Myers Squibb
• Bayer
• Amgen

What are the key trends in the Chronic Kidney Disease Drugs Market?

Use of advanced technology during R&D

An emerging trend in the CKD drug industry is the rising use of next-generation technologies such as high-throughput screening (HTS), Artificial Intelligence (AI), gene editing, and messenger RNA (mRNA)-based solutions. These technologies, along with other innovations, will help promote the industry growth rate during the projection period.

Precision medicine

The effectiveness of precision medicine in treating severe conditions has gained attention from CKD drug developers. The development of treatment plans customized to patients’ specific medical needs may open new avenues for extended growth in the industry.

The global chronic kidney disease drugs market is segmented as follows:

By Drug Class

• Angiotensin-Converting Enzyme (ACE) Inhibitors
• B-blockers
• Angiotensin Receptor Blockers (ARBs)
• Loop Diuretics
• Phosphate Binders
• Erythropoiesis -Stimulating Agents
• Calcium Channel Blockers
• Others

By Route of Administration

• Parenteral
• Oral

By Indication

• Polycystic Kidney Disease
• Hypertensive Neuropathy
• Glomerulonephritis
• Diabetic Neuropathy
• Others

By Distribution Channel

• Online Pharmacies
• Retail Pharmacies
• Hospital Pharmacies

By Region

• North America
  • The U.S.
  • Canada
• Europe
  • France 
  • The UK
  • Spain
  • Germany
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • South Africa
  • Rest of Middle East & Africa